It is transmitted by the bite of infected female phlebotomine sand flies. The disease manifests in three main clinical forms - cutaneous, mucocutaneous, and visceral leishmaniasis. The current treatment options include pentavalent antimonials, miltefosine, paromomycin, and liposomal amphotericin B. However, these drugs have issues such as toxicity, resistance, long treatment duration and require clinical administration under medical supervision. Hence, there is a high demand for developing alternative treatment options.
The Global Leishmaniasis Treatment Market Size is estimated to be valued at US$ 79.95 Bn in 2024 and is expected to exhibit a CAGR of 22% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the leishmaniasis treatment are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. Major pharma players are focused on developing new oral formulations and combination therapies to address the current treatment limitations.
The key opportunities in the market include the rising leishmaniasis disease prevalence globally especially in developing nations, growing health awareness, and significant public-private investments for R&D of novel drugs.
Globally, the market players are expanding their geographic footprint in high potential markets such as Asia Pacific and Latin America. Partnerships with local diagnostic, healthcare providers are helping penetrate untapped rural areas.
Market Drivers
Significant R&D investments by government and pharma companies in development of pipeline drugs is a key growth driver. Over 50 drugs are in various stages of clinical trials aimed at developing superior treatment options.
Market Restrains
Despite the increasing demand, the affordability and access to existing as well as emerging treatment regimens, especially in low and middle-income countries remains a challenge. This inhibits quicker adoption and market growth.
Segment Analysis
Visceral leishmaniasis and cutaneous leishmaniasis are the major sub-segments in the leishmaniasis treatment market. Visceral leishmaniasis is the dominant sub-segment currently as it is a potentially fatal disease if left untreated. According to recent studies, visceral leishmaniasis is more severe and life threatening than cutaneous leishmaniasis. The treatment also varies for both forms of the disease. Cutaneous Leishmaniasis is relatively less severe and can heal on its own in some cases. However, visceral leishmaniasis requires advanced treatment options like antileishmanial drugs and other therapeutics.
Global Analysis
North America region leads the leishmaniasis treatment market currently owing to increasing research activities for leishmaniasis treatment and presence of major pharmaceutical companies. The Asia Pacific region is projected to witness the highest growth during the forecast period due to rising awareness about the disease, growing population, unmet medical needs and improving healthcare infrastructure. Latin America also has a significant share as leishmaniasis is endemic to many countries in this region. The Middle East and Africa region is expected to offer lucrative opportunities for market players over the coming years attributed to growing investments in healthcare sector and rising patient population. Key players are focusing on emerging markets for long term growth prospects.
Get More Insights On This Topic: https://www.ukwebwire.com/leishmaniasis-treatment-market-size-share-analysis-2023-2030-2/
Comments
0 comment